Solara Active Pharma Sciences Limited (NSE: SOLARA | BSE: 541540, 890202)
Source: Solara Active Pharma Sciences Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)
📋 Quick Facts: Company Snapshot
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Solara Active Pharma Sciences Limited |
| Corporate Identity Number (CIN) | L24230MH2017PLC291636 |
| ISIN | INE624Z01016, IN9624Z01022 |
| NSE Symbol & BSE Scrip Code | NSE: SOLARA, SOLARAPP1 | BSE: 541540, 890202 |
| Date of Incorporation / Founding Year | February 23, 2017 |
| Founders / Key Founding Figures | Not disclosed in the report |
| Registered Office & Corporate Headquarters | Registered Office: ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai – 400 703, Maharashtra. Corporate Office: TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai – 600113, Tamil Nadu. |
| Telephone & Investor Relations Contact | Tel: +91 44 4344 6700 | Email: investors@solara.co.in |
| Chairman / Managing Director & CEO | Mr. R. Ramakrishnan (Chairman) | Mr. Sandeep Shashikantha Rao (Managing Director & CEO) |
| Chief Financial Officer (CFO) & Company Secretary (CS) | Mr. Sarat Kumar (Chief Financial Officer) | Ms. Pooja Jaya Kumar (Company Secretary & Compliance Officer) |
| Promoter & Holding Group | Arun Kumar Pillai and other promoter entities (Devicam Capital LLP, Pronomz Ventures LLP, etc.) |
| Industry / Sector Classification | Active Pharmaceutical Ingredients (APIs) / Pharmaceuticals |
| Total Employees / Permanent & Contractual Workforce (BRSR) | 1,669 permanent employees on rolls as of March 31, 2026 |
| Manufacturing Plants / Branches / Offices Count | 6 manufacturing facilities, 1 R&D center, and 3 corporate/sales offices |
| Countries / States Served | Active presence across 64 countries globally and 21 states domestically in India |
| Statutory Auditors | M/s. Deloitte Haskins & Sells LLP, Chartered Accountants |
| Registrar and Share Transfer Agent (RTA) | Cameo Corporate Services Limited, Chennai |
🏢 The Corporate Identity: Who They Are & Where They Came From
The Big Picture
Solara Active Pharma Sciences Limited is a leading global pure-play Active Pharmaceutical Ingredient (API) manufacturer, dedicated to improving global healthcare outcomes through science-led innovation and technology-driven solutions. Serving pharmaceutical customers across more than 60 countries, the company operates a robust business model supported by multi-product manufacturing assets, advanced process chemistry capabilities, and rigorous quality and regulatory compliance systems. With a strong presence in regulated international markets, Solara continues to build a resilient platform focused on finishing strong and building for growth.
The Founders, Promoters & Their Legacy
The company benefits from extensive industry expertise, established governance frameworks, and strategic guidance led by its promoter group and Board of Directors. Key leaders such as Mr. Arun Kumar Pillai bring decades of entrepreneurial and pharmaceutical domain experience, anchoring Solara’s long-term corporate vision. The organization’s foundation rests upon its core RITE values—Respect, Integrity, Transparency, and Efficiency—which drive its daily operational standards, compliance rigor, and stakeholder commitments.
The Journey: History & Evolution
Incorporated in February 2017, Solara was formed through the amalgamation of the API businesses of Strides Shasun Limited and SeQuent Scientific Limited. Over the years, the company has consolidated its manufacturing infrastructure, deepened its process chemistry competencies, and expanded its regulatory footprint across the United States, Europe, Japan, South Korea, and other international markets. Through continuous operational enhancements, disciplined cost optimization, and targeted research and development, Solara has transitioned toward a higher-growth, higher-margin base API business model.
The Corporate Umbrella
Solara operates as an independent listed corporate entity with specialized operational subsidiaries and investment structures. Its consolidated financial framework encompasses active entities dedicated to pharmaceutical solutions, chemistry laboratories, and international commercial execution across key geographic zones, ensuring streamlined operational oversight and global market reach.
⚙️ The Business Engine: What They Do & Where They Operate
The Core Divisions
The company operates primarily within a single unified business segment—the design, development, and manufacture of Active Pharmaceutical Ingredients (APIs)—while also offering specialized Contract Development and Manufacturing Organisation (CDMO) services to global pharmaceutical innovators and generic leaders.
The Product & Service Catalog
Solara’s commercial portfolio spans over 60 active pharmaceutical ingredients and a growing pipeline of molecules under development. The product catalog addresses critical therapeutic categories, including pain management, anti-infectives, anti-malarials, anthelmintics, anaesthetics, anticonvulsants, antipsychotics, and anti-hyperkalemia therapies. Additionally, the company commands specialized technological expertise in polymer-based APIs, iron-based products, and high-potency APIs (HPAPIs).
The Names You Know
Solara serves a diversified global clientele comprising leading generic and innovator pharmaceutical companies worldwide. Its products are integrated into essential finished dosage formulations distributed across major regulated healthcare markets.
Mapping the Domestic & Global Reach
The company maintains a vast commercial footprint spanning domestic operations across 21 Indian states and international exports reaching 64 countries. Regulated markets contribute a substantial majority—approximately 75%—of base business revenues, underpinned by longstanding customer relationships and stringent global regulatory approvals.
| Geography / Market Segment | FY 2025-26 Revenue (₹ in Crores) | FY 2024-25 Revenue (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Asia Pacific | 894.63 | 838.42 | +6.70% |
| Europe | 235.07 | 259.80 | -9.52% |
| South America | 91.01 | 59.83 | +52.11% |
| North America | 88.69 | 75.05 | +18.17% |
| Rest of the World | 20.75 | 8.36 | +148.21% |
| Total Revenue from Contracts with Customers | 1,330.15 | 1,241.46 | +7.14% |
The Brick & Mortar Footprint
Solara’s manufacturing infrastructure comprises six state-of-the-art API production plants located across India, approved by major global regulatory agencies including the USFDA, EU GMP, PMDA (Japan), KFDA (South Korea), WHO, MHRA (UK), COFEPRIS (Mexico), and TGA (Australia). These facilities include:
- Puducherry Facility: Multi-purpose API and intermediate facility with established local dispensary and healthcare outreach operations.
- Cuddalore Facility: Multi-purpose API and intermediate facility equipped with advanced environmental controls and effluent treatment systems.
- Mangaluru Facility: Specialized manufacturing site dedicated to niche and large-volume APIs and advanced drug intermediates.
- Mysuru Facility: Key intermediate manufacturing site with flexible process capabilities.
- Ambernath Facility: Multi-purpose API and intermediate production plant.
- Vizag Facility: State-of-the-art greenfield manufacturing site.
- Chennai R&D Centre: Advanced research and innovation hub equipped with analytical infrastructure, synthesis laboratories, and over 50 scientists driving process chemistry and product pipeline development.
📊 The Financial Health: The Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
| Financial Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 | Latest YoY (%) |
|---|---|---|---|---|
| Total Income / Revenue from Operations | 1,375.14 | 1,292.08 | 1,294.29 | +6.43% |
| EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization) | 191.54 | 213.84 | (92.03) | -10.43% |
| Profit / (Loss) After Tax (PAT) | (7.41) | 0.54 | (566.96) | N/M |
| Total Equity / Net Worth | 1,255.55 | 1,096.91 | 900.58 | +14.46% |
Earnings, Expenses, & Take-Home Profits
For the financial year ended March 31, 2026, Solara recorded total income of ₹1,375.14 crores compared to ₹1,292.08 crores in FY 2024-25, representing a steady top-line expansion driven by base business momentum. EBITDA stood at ₹191.54 crores, reflecting disciplined cost optimization and operational efficiencies that cushioned headwinds from commodity pricing pressures in the Ibuprofen segment. Net loss for the year stood at ₹7.41 crores.
| Particulars | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| 1. Revenue from Operations | |||
| Sale of products | 1,326.15 | 1,227.98 | +7.99% |
| Sale of services | 4.00 | 13.48 | -70.33% |
| Other operating revenues | 38.83 | 42.30 | -8.20% |
| 2. Other Income | |||
| Other income | 6.16 | 8.32 | -25.96% |
| Total Income (1 + 2) | 1,375.14 | 1,292.08 | +6.43% |
| 4. Expenses | |||
| Cost of materials consumed | 672.77 | 581.66 | +15.66% |
| Purchases of stock-in-trade | 3.49 | 5.75 | -39.30% |
| Changes in inventories of finished goods, stock-in-trade and work-in-progress | 8.25 | 39.00 | -78.85% |
| Employee benefits expenses | 219.20 | 211.69 | +3.55% |
| Finance costs | 94.75 | 114.81 | -17.47% |
| Depreciation and amortisation expenses | 99.68 | 99.25 | +0.43% |
| Other expenses | 278.52 | 239.38 | +16.35% |
| Total Expenses (4) | 1,376.66 | 1,291.54 | +6.59% |
| Profit / (Loss) Before Exceptional Item and Tax (3 – 4) | (1.52) | 0.54 | N/M |
| Exceptional Item – Loss | (5.89) | – | – |
| Profit / (Loss) Before Tax (7) | (7.41) | 0.54 | N/M |
| Profit / (Loss) for the Year (9) | (7.41) | 0.54 | N/M |
| Other Comprehensive Income (Net of Tax) | 2.85 | 0.98 | +190.82% |
| Total Comprehensive Income / (Loss) for the Year | (4.56) | 1.52 | N/M |
Assets, Borrowings, & Net Worth
The company maintains a robust balance sheet backed by substantial tangible asset blocks and active working capital management. Total equity stood at ₹1,255.55 crores as of March 31, 2026, bolstered by equity infusions through rights issue proceeds and stock option exercises.
| Particulars | As at March 31, 2026 (₹ in Crores) | As at March 31, 2025 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| A. ASSETS | |||
| I. Non-current assets | |||
| Property, plant and equipment | 793.18 | 738.68 | +7.38% |
| Right-of-use assets | 57.23 | 57.74 | -0.88% |
| Capital work in progress | 204.79 | 280.05 | -26.87% |
| Investment property | – | 2.28 | – |
| Goodwill | 364.90 | 364.90 | 0.00% |
| Other intangible assets | 22.20 | 29.80 | -25.50% |
| Investments (Non-current) | 1.62 | 1.70 | -4.71% |
| Other financial assets (Non-current) | 16.74 | 16.32 | +2.57% |
| Income tax assets (net) | 6.63 | 4.52 | +46.68% |
| Other non-current assets | 7.20 | 7.12 | +1.12% |
| Total Non-Current Assets | 1,474.49 | 1,503.11 | -1.90% |
| II. Current assets | |||
| Inventories | 317.87 | 317.90 | -0.01% |
| Investments (Current) | 3.00 | – | – |
| Trade receivables | 438.72 | 326.57 | +34.34% |
| Cash and cash equivalents | 4.48 | 3.95 | +13.42% |
| Bank balances other than cash and cash equivalents | 45.86 | 0.16 | +28562.50% |
| Loans (Current) | 0.03 | 0.02 | +50.00% |
| Other financial assets (Current) | 6.54 | 12.36 | -47.09% |
| Other current assets | 41.60 | 67.77 | -38.62% |
| Total Current Assets | 858.10 | 728.73 | +17.75% |
| Total Assets (I + II) | 2,332.59 | 2,231.84 | +4.51% |
| B. EQUITY AND LIABILITIES | |||
| I. Equity | |||
| Equity share capital | 44.51 | 40.25 | +10.58% |
| Other equity | 1,208.37 | 1,053.99 | +14.65% |
| Non-controlling interests | 2.67 | 2.67 | 0.00% |
| Total Equity | 1,255.55 | 1,096.91 | +14.46% |
| II. Liabilities | |||
| 1. Non-current liabilities | |||
| Non-current borrowings | 110.45 | 113.86 | -2.99% |
| Lease liabilities (Non-current) | 19.21 | 17.77 | +8.10% |
| Other financial liabilities (Non-current) | – | 0.42 | – |
| Provisions (Non-current) | 53.47 | 58.77 | -9.02% |
| Total Non-Current Liabilities | 183.13 | 190.82 | -4.03% |
| 2. Current liabilities | |||
| Current borrowings | 554.09 | 662.20 | -16.33% |
| Lease liabilities (Current) | 2.81 | 2.25 | +24.89% |
| Trade payables (MSME dues) | 19.19 | 37.99 | -49.49% |
| Trade payables (Other dues) | 254.71 | 209.61 | +21.52% |
| Other financial liabilities (Current) | 32.86 | 18.91 | +73.77% |
| Provisions (Current) | 13.88 | 2.23 | +522.42% |
| Current tax liabilities (net) | 0.01 | 0.01 | 0.00% |
| Other current liabilities | 16.36 | 10.91 | +49.95% |
| Total Current Liabilities | 893.91 | 944.11 | -5.32% |
| Total Liabilities | 1,077.04 | 1,134.93 | -5.10% |
| Total Equity and Liabilities | 2,332.59 | 2,231.84 | +4.51% |
Cash Flow: Tracking the Money Movement
Operating cash generation remained strong with net cash generated from operating activities at ₹152.91 crores for FY 2025-26, reflecting disciplined working capital management and stable operational inflows.
| Particulars | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Net cash flow generated from operating activities (A) | 152.91 | 212.82 | -28.15% |
| Purchase of Property, Plant and Equipment (CapEx) & Intangible assets | (52.82) | (39.94) | +32.25% |
| Net cash flow utilised in investing activities (B) | (98.83) | (36.83) | +168.34% |
| Net cash flow utilised in financing activities (C) | (53.55) | (180.48) | -70.33% |
| Net increase / (decrease) in cash and cash equivalents (A + B + C) | 0.53 | (4.49) | N/M |
| Cash and cash equivalents at the beginning of the year | 3.95 | 8.44 | -53.20% |
| Cash and cash equivalents at the end of the year | 4.48 | 3.95 | +13.42% |
Funding the Future: CapEx, CWIP & R&D Spending
Capital work-in-progress stood at ₹204.79 crores as of March 31, 2026, driven by ongoing capacity expansion and infrastructure projects at manufacturing sites such as Vizag. R&D recurring expenditures amounted to ₹31.11 crores, with capital investments in R&D reaching ₹4.17 crores, fueling complex chemistry and product filings.
🗺️ The Corporate Family Tree: Structure & Investments
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
| Name of Subsidiary | Relationship | Country | % Shareholding | Turnover (₹ in Crores) | Profit / (Loss) After Tax (₹ in Crores) |
|---|---|---|---|---|---|
| Chemsynth Laboratories Private Limited | Subsidiary | India | 49% | 0.00 | (0.40) |
| Synthix Global Pharma Solutions Limited | Subsidiary | India | 100% | 0.00 | (2.48) |
| Shasun USA Inc | Subsidiary | USA | 100% | 0.00 | (4.54) |
Strategic Investments & Treasury Holdings
The Group holds unquoted equity investments in entities such as Tulysan Nec Limited, Watsun Infrabuild Private Limited, Vaayu Renewable Energy (Muthamalpuram) Pvt. Ltd., Huoban Energy 3 Private Limited, and SIPCOT Industrial Common Utilities Limited, alongside short-term investments in mutual funds amounting to ₹3.00 crores.
👥 Power & Control: Who Pulls the Strings?
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Ramakrishnan Rajagopal | Chairman & Independent Director | 00161542 | Independent Director |
| Dr. Kausalya Santhanam | Independent Director | 06999168 | Independent Director |
| Prof. Rajendra Kumar Srivastava | Independent Director | 07500741 | Independent Director |
| Mr. Rajiv Vijay Nabar | Independent Director | 10383397 | Independent Director |
| Mr. Arun Kumar Pillai | Non-Executive Director | 00084845 | Non-Executive Director |
| Mr. Manish Gupta | Non-Executive Director | 06805265 | Non-Executive Director |
| Mr. Sandeep Shashikantha Rao | Managing Director & CEO | 10838251 | Executive Director (KMP) |
| Mr. Mohanraj Sanjeevi | Whole Time Director & Chief Human Resources Officer | 08420411 | Executive Director (KMP) |
| Mr. Sarat Kumar | Chief Financial Officer | – | Key Managerial Personnel |
| Ms. Pooja Jaya Kumar | Company Secretary & Compliance Officer | – | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
| Category of Shareholder | Number of Shares | % of Total Shares |
|---|---|---|
| Promoters | 2,02,31,281 | 42.00% |
| Mutual Funds | 5,67,155 | 1.18% |
| Banks, Financial Institutions, Insurance Companies | 15,209 | 0.03% |
| Foreign Portfolio Investors / FIIs | 55,83,042 | 11.59% |
| Non-resident Indians / Foreign Nationals / OCBs | 18,76,067 | 3.89% |
| Bodies Corporates / NBFC | 40,07,081 | 8.32% |
| Others (Indian Public, Trusts, IEPF, AIF, Central/State Govt., etc.) | 1,58,91,727 | 32.99% |
| Total | 4,81,71,562 | 100.00% |
🎯 The Strategic Outlook: Future Plans & Potential Pitfalls
Competitive Advantages & Economic Moats
Solara’s competitive strength lies in its established regulatory track record with major global agencies (including USFDA, EDQM, and PMDA), an integrated manufacturing infrastructure across six specialized plants, deep process chemistry and R&D capabilities, and longstanding relationships with global pharmaceutical leaders. Regulated markets contribute nearly 75% of base business revenues, providing a stable, high-margin foundation that insulates the company from commodity pricing cycles.
What Could Go Wrong? Key Challenges & Business Risks
The company faces headwinds from persistent pricing pressures, global overcapacity, and subdued margins within the commodity Ibuprofen segment. Additionally, pharmaceutical manufacturing remains exposed to foreign exchange volatility, raw material cost fluctuations, strict global regulatory audit outcomes, and potential supply chain disruptions.
The Next Chapter: Growth & CapEx Initiatives
Strategic priorities for the future include expanding high-margin base API capacities through debottlenecking, accelerating research and development through continuous DMF filings and complex generic molecules, deepening market penetration across regulated and emerging geographies, and maintaining strict financial discipline through working capital optimization and debt reduction.
The Verdict: Strategic Outlook & Conclusion
By successfully finishing strong in its core base business and executing rigorous cost discipline, Solara has fortified its operational foundation. With clear strategic intent focused on portfolio differentiation, operational excellence, and robust quality governance, Solara enters the upcoming fiscal years well-positioned to deliver sustainable growth and long-term value creation for all stakeholders.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.solara.co.in